Search Results
Your search for ,NOt matches 22378 pages
Showing 951 - 1000Multidisciplinary Program Doubles Lung Cancer Screening Rates
Researchers have created a roadmap to improve national lung cancer screening rates that doubled lung cancer screening rates through their multidisciplinary lung cancer screening program, according to a study published in NEJM Catalyst. “Our biggest success was not only screening a high percentage...
First-Line PD-1/PD-L1 Inhibitors vs BRAF Plus MEK Inhibitors in BRAF V600E–Mutated Metastatic NSCLC
In a retrospective cohort study (FRONT-BRAF) reported in The Lancet Oncology, Di Federico et al found that first-line PD-1 or PD-L1 inhibitors with or without platinum-based chemotherapy were associated with improved overall survival compared with BRAF and MEK inhibitors in patients with metastatic ...
Lisaftoclax Regimens Effective in Plasma Cell Disorders
Lisaftoclax, an investigational BCL2 inhibitor, in combination with pomalidomide/dexamethasone (Pd) or daratumumab/lenalidomide/dexamethasone (DRd) led to improved outcomes for patients with relapsed or refractory multiple myeloma and for patients with AL amyloidosis, according to findings from a...
Cutaneous T-Cell Lymphoma: Use of Durvalumab Alone or With Lenalidomide Under Study in Phase II Trial
In a randomized phase II trial, Christiane Querfeld, MD, PhD, and colleagues investigated the effects of a PD-L1–blocking strategy for targeting both the innate and adaptive immune systems in cutaneous T-cell lymphoma (CTCL). At the 2025 Society of Hematologic Oncology (SOHO) Annual Meeting,1 Dr....
Risk of Colorectal Subsequent Malignant Neoplasms in Childhood Cancer Survivors
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Owens et al identified the risks of colorectal subsequent malignant neoplasms (SMNs) associated with colorectal-specific radiotherapy (RT) doses and chemotherapy doses among 5-year survivors of childhood...
Survival With Dual CTLA-4 and PD-L1/PD-1 Blockade in Advanced NSCLC
In a systematic review and reconstructed individual-patient meta-analysis reported in The Lancet Oncology, Di Federico et al found that dual CTLA-4 and PD-L1 or PD-1 blockade did not result in improved long-term survival overall vs single PD-L1 or PD-1 blockade in patients with advanced non–small...
AML: Alliance Global Study Challenges Age-Based Treatment Decisions
An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group has revealed that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic. Their findings were published by...
Individuals With Rare Cancers Present Distinct Diagnosis Patterns; Many Experience Treatment Delays
Rare cancers—defined as fewer than 6 cases per 100,000 people per year—are understudied in the United States, and patients with rare cancers may experience unique challenges. In a recent, large study led by the American Cancer Society (ACS), scientists found that patients diagnosed with rare...
Chemotherapy-Free Regimen vs Standard Immunochemotherapy in Mantle Cell Lymphoma in Older Patients
In a phase II/III study (ENRICH) reported in The Lancet, Lewis et al found that the chemotherapy-free combination of ibrutinib plus rituximab prolonged progression-free survival vs standard immunochemotherapy in patients aged 60 years or older with previously untreated mantle cell lymphoma. Study...
10-Year Incidence of Second Cancers in HPV-Positive Oropharyngeal Cancer
At 10 years, the cumulative incidence of radiation-induced second malignancies in patients receiving definitive radiation therapy for human papillomavirus (HPV)–associated oropharyngeal cancers was 1.74%, according to findings culled from the Cleveland Clinic Cancer Institute database. These...
Alcohol and Cancer Risk: Is a Drop Too Much?
In 2022, Congress requested a scientific review from the National Academies of Sciences, Engineering, and Medicine (NASEM) to study the associated risks of cancer and other health conditions and the use of alcohol. The concern was that the health risks associated with low-to-moderate consumption of ...
Study Confirms It’s ‘Never Too Late’ to See Survival Benefits From Quitting Smoking—Even With Late-Stage Cancer
New research published by Tohmasi et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that people with cancer who quit smoking had a much lower risk of dying within 2 years compared to those who kept smoking. Researchers followed more than 13,000 individuals with cancer,...
First-Line Ribociclib at 400 vs 600 mg in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (AMALEE) reported in JAMA Oncology, Cardoso et al found that a first-line ribociclib dose of 400 mg was not noninferior to a dose of 600 mg in patients with newly diagnosed hormone receptor–positive, HER2-negative advanced breast cancer. Study Details In the open-label...
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...
Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk
In a nationwide study published in JCO Oncology Practice, Wolswinkel et al evaluated the long-term oncologic safety of fertility-sparing surgery (FSS) compared with hysterectomy in women with early-stage cervical cancer. The study—one of the largest of its kind—addresses a critical question for...
Creatine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Ziftomenib in Relapsed or Refractory NPM1-Mutant AML
As reported in the Journal of Clinical Oncology by Wang et al, a phase I/II trial (KOMET-001) has shown activity of the oral menin inhibitor ziftomenib in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Study Details In the phase II portion of the trial, 92 patients...
Advanced Biliary Tract Cancer: Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin
Based on the results of the multicenter phase III NEXT trial published by Jeong et al in JAMA Network Open, the addition of a polymeric micellar paclitaxel to standard chemotherapy with gemcitabine plus cisplatin did not improve overall survival in patients with previously untreated advanced...
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
In individuals younger than age 50 undergoing a colonoscopy, greater odds for having colorectal cancer were observed among those who presented with rectal bleeding, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the...
Mastectomy Linked to Worsened Sexual Health and Body Image After Surgery, Study Finds
Although mastectomy is often a necessary and life-saving treatment option for many women with breast cancer, the surgery may contribute to worse sexual health, body image, and several other physical and emotional challenges after surgery, according to a recent systematic review on the effects of...
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
When seeking a surgeon for treatment, providing emotional support and helping patients manage expectations are among the top areas of communication valued by patients, according to a recent systematic review. The research was presented at the 2025 American College of Surgeons (ACS) Clinical...
Considerations on Cancer Drug Development
In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....
FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...
PD-1 Inhibitor Approved for Adjuvant Treatment of CSCC
On October 8, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation therapy. C-POST Efficacy was evaluated in C-POST (ClinicalTrials.gov ...
Inflammatory Activity and Cancer-Related Fatigue in Early Breast Cancer
Research published in Cancer revealed that inflammatory responses may be tied to cancer-related fatigue and certain inflammatory activities may lead to distinct dimensions of fatigue in women with early-stage breast cancer. “Our findings indicate that inflammation plays a role in some aspects of...
Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC
In the phase III HARMONi trial, when ivonescimab was given with carboplatin plus pemetrexed, vs the chemotherapy regimen alone, after a third-generation tyrosine kinase inhibitor, patients with EGFR-mutated non–small cell lung cancer (NSCLC) had a significant delay in disease progression.1...
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Chemoradiation with a pulsed low-dose–rate technique led to lower-than-usual rates of severe esophagitis without compromising efficacy in patients with esophageal and non–small cell lung cancer (NSCLC), according to findings from a single-arm phase I study presented as a poster during the American...
Predicting Future Breast Cancer Outcomes: Efficacy of a Polygenic Risk Score
Studies show that if left untreated, between 20% and 40% of ductal carcinoma in situ (DCIS) lesions may evolve into invasive breast cancer over time. And, according to the American Cancer Society, women diagnosed with lobular carcinoma in situ (LCIS) have between a 7 and 12 times higher risk of...
Prior Authorization Is Burdensome for Patients and Results in Treatment Delays, Financial Strain, and Stress, Survey Finds
The process of obtaining insurance prior authorization before a medical procedure, service, or medication prescription has typically been left to clinicians. However, as cancer therapies grow increasingly complex, the burden of navigating insurance prior authorization is increasingly being shared...
Study Finds Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers
Although industry-sponsored cancer clinical trials often focus on single-agent drug trials, federally funded cancer clinical trials are more likely to investigate drug combinations with other treatments, including biologics or radiation therapy. An analysis by Joseph M. Unger, PhD, MS, Professor,...
Network of Cancer Drug Repositories Improves Access to Treatment, Reduces Waste
A new study found that implementing a network of cancer drug repositories (CDRs) improved access to cancer medications and eliminated unnecessary medication waste by allowing people to donate unopened or unused medications that would otherwise be wasted. This resulted in patients with cancer...
Breast Volume Preservation Comparable After Five-Fraction Whole- or Partial-Breast Radiotherapy
No significant differences were observed in breast volume loss between five-fraction whole-breast and partial-breast radiation therapy in patients with breast cancer who underwent prior partial mastectomy, according to the results of a study presented in a poster during the American Society for...
Genetic Modification of the AJCC Classification for Papillary Thyroid Cancer
In an international, multicenter retrospective cohort study reported in The Lancet Oncology, Xing et al found that incorporating the genetic status of BRAF and TERT genes into the American Joint Committee on Cancer (AJCC) staging system for papillary thyroid cancer resulted in a modification of...
Dexamethasone-Sparing Regimen for Frail Patients With Newly Diagnosed Multiple Myeloma
In a French phase III trial (IFM2017-03) reported in The Lancet Oncology, Manier et al found that a dexamethasone-sparing regimen of daratumumab plus lenalidomide improved progression-free survival vs lenalidomide plus dexamethasone in patients with frailty and newly diagnosed multiple myeloma....
Immunotherapy Addition Yields QOL Benefits in Limited-Stage Small Cell Lung Cancer
Clinically meaningful improvements in longer-term quality of life were achieved with the addition of atezolizumab immunotherapy to chemoradiation in patients with limited-stage small cell lung cancer (LS-SCLC), according to patient-reported outcome findings from the NRG LU005 trial presented during ...
Association of Survival With Treatment Recommendation and Receipt in Older Patients With Early-Stage Cervical Cancer
In a retrospective cohort study reported in JAMA Network Open, Suk et al identified the association of survival with receipt of recommended treatment and nonreceipt of nonrecommended treatment among patients aged ≥ 65 years with newly diagnosed early-stage cervical cancer. Study Details The study...
Dose-Intensified Proton Therapy for Newly Diagnosed Glioblastoma
Dose intensification of proton radiation therapy led to improved overall survival for patients with newly diagnosed glioblastoma, according to findings from a cohort of the phase II NRG-BN001 trial, which were presented as late-breaking research during the 2025 American Society for Radiation...
9/11 First Responder Study Shows How Toxic Exposures May Lead to Blood Cancers
A recent study has found that mutations in blood-forming cells may explain the increased risk for leukemia and other blood disorders among first responders exposed to the 9/11 World Trade Center (WTC) disaster site and its toxic dust. The study also points to a novel strategy for use against...
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The initial report in 2024 revealed a rate of complete remission or complete remission with incomplete...
Cytogenetic Remission Linked to Improved Survival in Patients With AML
Patients with acute myeloid leukemia (AML) who achieve cytogenetic remission may have better survival outcomes than patients with new or sustained cytogenetic abnormalities, according to findings from a study published in the American Journal of Hematology. The study elucidated how cytogenetic...
Medicare Telehealth Flexibilities and CMS Operations During Government Shutdown
The U.S. government shut down on October 1 after lawmakers were unable to reach a funding agreement. The date also marked the deadline to extend the Medicare telehealth flexibilities that have been in place since the COVID-19 public health emergency (PHE). As such, telehealth flexibilities have...
FDA Approves Combination Regimen for Extensive-Stage SCLC
On October 2, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for maintenance treatment of adults with extensive-stage small cell lung cancer (SCLC) whose disease...
Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer
In a Brazilian phase II trial (HERCULES; LACOG 0218) reported in JAMA Oncology, Maluf et al found that pembrolizumab plus platinum-based chemotherapy showed activity in patients with advanced penile squamous cell carcinoma. The investigators explained, “Advanced penile squamous cell carcinoma is...
CD19 CAR T-Cell Therapy May Be Effective in Treating Resistant Ulcerative Colitis
Studies show that individuals diagnosed with ulcerative colitis have approximately a twofold increased risk of developing colorectal cancer compared with the general population. A study investigating treatment with autologous chimeric antigen receptor (CAR) T cells targeting the CD19 antigen in a...
In Extensive-Stage Small Cell Lung Cancer, Novel Maintenance Regimen Boosts Overall Survival
The phase Ib DeLLphi-303 trial has reported overall survival data for a novel maintenance regimen in extensive-stage small cell lung cancer following first-line chemoimmunotherapy. Patients treated with the bispecific T-cell engager tarlatamab-dlle plus a PD-L1 inhibitor had a median overall...
CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas
For patients with recurrent retroperitoneal sarcomas that cannot be treated surgically, treatment choices are limited. These tumors can grow in the abdomen adjacent to vital organs or enmeshed within the bowel. Given their radioresistant nature, they require high doses of radiation that risk...
Sunvozertinib in Platinum-Pretreated NSCLC With EGFR Exon 20 Insertion Mutations
In a phase II trial (WU-KONG1B) reported in the Journal of Clinical Oncology, Yang et al found that the EGFR tyrosine kinase inhibitor sunvozertinib was active at both dose levels tested in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations....
Intermediate-Risk Prostate Cancer: Shorter Radiation Improves Patient Experience, But Not Disease Control
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation...
Oropharyngeal Cancer Quality-of-Life Outcomes: IMRT vs Proton-Beam Therapy
A new phase III clinical trial has found that intensity-modulated radiation therapy (IMRT) and proton-beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. The TORPEdO trial, a randomized study conducted across ...
SABR May Be Comparable to Surgery for Early-Stage NSCLC
Stereotactic radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), according to 10-year results from the STARS trial presented at the American Society for Radiation Oncology (ASTRO)...
